articleNature MedicineFeb 27, 2026Closed access

Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial

JJJan-Jaap J. MellemaCFChantal F. StockemCHCameron HerbertsSKSamantha K. CheungDJDaniël J. Vis

The Netherlands Cancer Institute · Texas Oncology · +9 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

4
total citations
FWCI
81.07
Percentile
99%
References
25
Too recent for citation history.

Authors

22

Topics & keywords

Topics
Keywords
  • Nivolumab
  • Ipilimumab
  • Clinical endpoint
  • Chemoradiotherapy
  • Adverse effect
  • Bladder cancer
  • Immunotherapy
  • Perioperative
No related works found for this paper.

Funding